AAAAAA

   
Results: 1-12 |
Results: 12
Characterization of xenobiotic-metabolizing cytochrome P450 (CYP) forms inringed and grey seals from the Baltic Sea and reference sites
Authors: Nyman, M Raunio, H Taavitsainen, P Pelkonen, O
Citation: M. Nyman et al., Characterization of xenobiotic-metabolizing cytochrome P450 (CYP) forms inringed and grey seals from the Baltic Sea and reference sites, COMP BIOC C, 128(1), 2001, pp. 99-112
Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: Development of a high-sensitivity glucuronidation assay for human tissue
Authors: Luukkanen, L Mikkola, J Forsman, T Taavitsainen, P Taskinen, J Elovaara, E
Citation: L. Luukkanen et al., Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: Development of a high-sensitivity glucuronidation assay for human tissue, DRUG META D, 29(8), 2001, pp. 1096-1101
An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
Authors: Andersson, TB Sjoberg, H Hoffmann, KJ Boobis, AR Watts, P Edwards, RJ Lake, BG Price, RJ Renwick, AB Gomez-Lechon, MJ Castell, JV Ingelman-Sundberg, M Hidestrand, M Goldfarb, PS Lewis, DFV Corcos, L Guillouzo, A Taavitsainen, P Pelkonen, O
Citation: Tb. Andersson et al., An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant, DRUG META D, 29(5), 2001, pp. 712-720
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene
Authors: Taavitsainen, P Juvonen, R Pelkonen, O
Citation: P. Taavitsainen et al., In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene, DRUG META D, 29(3), 2001, pp. 217-222
Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems
Authors: Pelkonen, O Myllynen, P Taavitsainen, P Boobis, AR Watts, P Lake, BG Price, RJ Renwick, AB Gomez-Lechon, MJ Castell, JV Ingelman-Sundberg, M Hidestrand, M Guillouzo, A Corcos, L Goldfarb, PS Lewis, DFV
Citation: O. Pelkonen et al., Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems, XENOBIOTICA, 31(6), 2001, pp. 321-343
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
Authors: Kivisto, KT Wang, JS Backman, JT Nyman, L Taavitsainen, P Anttila, M Neuvonen, PJ
Citation: Kt. Kivisto et al., Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole, EUR J CL PH, 57(1), 2001, pp. 37-42
Selegiline metabolism and cytochrome P450 enzymes: In vitro study in humanliver microsomes
Authors: Taavitsainen, P Anttila, M Nyman, L Karnani, H Salonen, JS Pelkonen, O
Citation: P. Taavitsainen et al., Selegiline metabolism and cytochrome P450 enzymes: In vitro study in humanliver microsomes, PHARM TOX, 86(5), 2000, pp. 215-221
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans
Authors: Wang, JS Backman, JT Taavitsainen, P Neuvonen, PJ Kivisto, KT
Citation: Js. Wang et al., Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans, DRUG META D, 28(8), 2000, pp. 959-965
In vitro inhibition screening of human hepatic P-450 enzymes by five angiotensin-II receptor antagonists
Authors: Taavitsainen, P Kiukaanniemi, K Pelkonen, O
Citation: P. Taavitsainen et al., In vitro inhibition screening of human hepatic P-450 enzymes by five angiotensin-II receptor antagonists, EUR J CL PH, 56(2), 2000, pp. 135-140
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro
Authors: Wang, JS Backman, JT Wen, X Taavitsainen, P Neuvonen, PJ Kivisto, KT
Citation: Js. Wang et al., Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro, PHARM TOX, 85(5), 1999, pp. 201-205
Midazolam alpha-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole
Authors: Wang, JS Wen, X Backman, JT Taavitsainen, P Neuvonen, PJ Kivisto, KT
Citation: Js. Wang et al., Midazolam alpha-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole, PHARM TOX, 85(4), 1999, pp. 157-161
Inhibition and induction of human cytochrome P450 (CYP) enzymes
Authors: Pelkonen, O Maenpaa, J Taavitsainen, P Rautio, A Raunio, H
Citation: O. Pelkonen et al., Inhibition and induction of human cytochrome P450 (CYP) enzymes, XENOBIOTICA, 28(12), 1998, pp. 1203-1253
Risultati: 1-12 |